Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 14/20 | 0.69 |
| ▸ | PDE4A | P27815 | 12/20 | 0.69 |
| ▸ | PDE4C | Q08493 | 12/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 12/20 | 0.69 |
| ▸ | CA1 | P00915 | 5/20 | 0.62 |
| ▸ | CA2 | P00918 | 5/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.62 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | PDE1A | P54750 | 1/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.48 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5583348 | 1.00 | PDE4B (0.69) | PDE4BPDE4APDE4CPDE4DCA1 | |
| SCHEMBL8076402 | 0.85 | CA1 (0.62) | PDE4BPDE4APDE4CPDE4DCA1 | |
| SCHEMBL2529312 | 0.82 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4DPDE3A | |
| SCHEMBL26425459 | 0.82 | PDE4B (0.61) | PDE4BPDE4APDE4CPDE4DCA1 | |
| SCHEMBL23512999 | 0.82 | PDE4B (0.82) | PDE4BPDE4APDE4CPDE4DPDE3A | |
| SCHEMBL10053217 | 0.78 | PDE4A (0.45) | PDE4BPDE4APDE4CPDE4DCA1 | |
| SCHEMBL564786 | 0.78 | CA1 (0.65) | PDE4BPDE4APDE4CPDE4DCA1 | |
| SCHEMBL26425447 | 0.78 | PDE4B (0.50) | PDE4BPDE4APDE4CPDE4DCA1 | |
| SCHEMBL18612878 | 0.77 | PDE4A (0.44) | PDE4BPDE4APDE4CPDE4DCA1 | |
| SCHEMBL10220172 | 0.77 | CA1 (0.62) | PDE4BPDE4APDE4CPDE4DCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240358728-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, LLC (US) | 2024-10-31 | — | — | US | disclosed |
| US-11834466-B2 | Benzoxaborole compounds and formulations thereof | 5METIS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834466-B2 | Benzoxaborole compounds and formulations thereof | 5METIS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230008130-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2023-01-12 | — | — | US | disclosed |
| EP-3842420-B1 | HETEROARYL INHIBITORS OF PDE4 | TETRA DISCOVERY PARTNERS LLC (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-3280262-B1 | SYNERGISTIC BENZOXABOROLE-CONTAINING ANTI-FUNGICIDAL COMPOSITION | PENN STATE RES FOUND (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-3280262-B1 | SYNERGISTIC BENZOXABOROLE-CONTAINING ANTI-FUNGICIDAL COMPOSITION | PENN STATE RES FOUND (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-3148551-B1 | VOLATILE APPLICATIONS AGAINST PATHOGENS | AGROFRESH INC (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3842420-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners LLC (US) | 2021-06-30 | — | — | EP | disclosed |
| WO-2021108683-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2021-06-03 | — | — | WO | disclosed |
| EP-2015757-A2 | HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE | Anacor Pharmaceuticals, Inc. (US) | 2009-01-21 | — | — | EP | disclosed |
| EP-1976536-A2 | BORON-CONTAINING SMALL MOLECULES | Anacor Pharmaceuticals, Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007146965-A2 | COMPOUNDS FOR THE TREATMENT OF PERIODONTAL DISEASE | ANACOR PHARMACEUTICALS, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070293457-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, LLC | 2007-12-20 | — | — | US | disclosed |
| US-20070286822-A1 | Compounds for the Treatment of Periodontal Disease | ANACOR PHARMACEUTICALS INC. (US) | 2007-12-13 | — | — | US | disclosed |
| WO-2007131072-A2 | HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE | ANACOR PHARMACEUTICALS, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| US-20070265226-A1 | Hydrolytically-Resistant Boron-Containing Therapeutics And Methods Of Use | ANACOR PHARMACEUTICALS (US) | 2007-11-15 | — | — | US | disclosed |
| WO-2007078340-A2 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155699-A1 | Boron-containing small molecules | ANACOR PHARMACEUTICALS (US) | 2007-07-05 | — | — | US | disclosed |
| US-20060234981-A1 | Boron-containing small molecules | ANACOR PHARMACEUTICALS (US) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060234981-A1 | Boron-containing small molecules | ETF1, POLR1C, DPM1 | PDE4B 4444/4885PDE4A 4397/4885PDE4C 4585/4885 |
| US-20070286822-A1 | Compounds for the Treatment of Periodontal Disease | BPGM, HMBS, PPIP5K2 | PDE4B 1043/4885PDE4A 1049/4885PDE4C 1262/4885 |
| US-20230008130-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | NFKBIA, LITAF, LRBA | PDE4B 948/4885PDE4A 1385/4885PDE4C 2189/4885 |
| US-20240358728-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | NFKBIA, LITAF, LRBA | PDE4B 948/4885PDE4A 1385/4885PDE4C 2189/4885 |
| US-11834466-B2 | Benzoxaborole compounds and formulations thereof | SSB, NONO, LRBA | PDE4B 4135/4885PDE4A 4690/4885PDE4C 4711/4885 |
| US-20070293457-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | NFKBIA, LITAF, TNF | PDE4B 1058/4885PDE4A 1336/4885PDE4C 2209/4885 |
| US-20070155699-A1 | Boron-containing small molecules | ETF1, POLR1C, DPM1 | PDE4B 4444/4885PDE4A 4397/4885PDE4C 4585/4885 |
| US-20070265226-A1 | Hydrolytically-Resistant Boron-Containing Therapeutics And Methods Of Use | GAA, BTD, MANBA | PDE4B 2060/4885PDE4A 3014/4885PDE4C 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.